Genomic Health Company Profile (NASDAQ:GHDX)

About Genomic Health

Genomic Health logoGenomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GHDX
  • CUSIP: 37244C10
Key Metrics:
  • Previous Close: $29.97
  • 50 Day Moving Average: $29.01
  • 200 Day Moving Average: $27.60
  • 52-Week Range: $20.54 - $35.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 999.00
  • P/E Growth: -11.35
  • Market Cap: $999.38M
  • Outstanding Shares: 33,346,000
  • Beta: 0.34
  • Net Margins: -8.84%
  • Return on Equity: -21.02%
  • Return on Assets: -15.99%
  • Current Ratio: 3.54%
  • Quick Ratio: 3.54%
Additional Links:
Companies Related to Genomic Health:

Analyst Ratings

Consensus Ratings for Genomic Health (NASDAQ:GHDX) (?)
Ratings Breakdown: 2 Sell Ratings, 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $32.44 (8.26% upside)

Analysts' Ratings History for Genomic Health (NASDAQ:GHDX)
DateFirmActionRatingPrice TargetDetails
8/17/2016Jefferies GroupBoost Price TargetHold$25.00 -> $27.00View Rating Details
8/5/2016Canaccord GenuityReiterated RatingBuy$38.00View Rating Details
8/3/2016Bank of America Corp.Set Price TargetSell$28.00View Rating Details
6/21/2016Leerink SwannReiterated RatingBuyView Rating Details
2/11/2016Cowen and CompanyReiterated RatingBuyView Rating Details
2/11/2016Barclays PLCLower Price TargetUnderweight$27.00 -> $25.00View Rating Details
2/11/2016Piper Jaffray Cos.Reiterated RatingIn-Line$32.00 -> $31.00View Rating Details
11/4/2015Raymond James Financial Inc.UpgradeMarket Perform -> Outperform$29.00View Rating Details
11/2/2015JMP SecuritiesBoost Price TargetOutperform$34.00 -> $36.00View Rating Details
5/28/2015Credit Suisse Group AGReiterated RatingNeutralView Rating Details
2/11/2015William BlairReiterated RatingOutperformView Rating Details
12/19/2014Wells Fargo & Co.Initiated CoverageMarket PerformView Rating Details
(Data available from 10/27/2014 forward)


Earnings History for Genomic Health (NASDAQ:GHDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016Q316($0.09)$83.24 millionN/AView Earnings Details
8/2/2016Q216($0.18)($0.18)$81.27 million$81.97 millionViewN/AView Earnings Details
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details
5/5/2015Q115($0.26)($0.30)$68.20 millionViewN/AView Earnings Details
2/10/2015Q414($0.22)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details
8/5/2014Q214($0.26)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details
8/8/2012($0.02)$0.06ViewN/AView Earnings Details
5/2/2012($0.02)$0.02ViewN/AView Earnings Details
2/6/2012$0.09$0.08ViewN/AView Earnings Details
11/1/2011$0.03$0.10ViewN/AView Earnings Details
8/3/2011$0.02$0.08ViewN/AView Earnings Details
5/3/2011$0.02($0.01)ViewN/AView Earnings Details
2/8/2011$0.06$0.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Genomic Health (NASDAQ:GHDX)
Current Year EPS Consensus Estimate: $-0.48 EPS
Next Year EPS Consensus Estimate: $0.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.25)($0.07)($0.17)
Q2 20167($0.20)($0.01)($0.11)
Q3 20164($0.15)($0.01)($0.08)
Q4 20165($0.05)$0.02($0.01)
Q1 20171$0.01$0.01$0.01
Q2 20171$0.01$0.01$0.01
Q3 20171$0.01$0.01$0.01
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)


Dividend History for Genomic Health (NASDAQ:GHDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Genomic Health (NASDAQ:GHDX)
Insider Ownership Percentage: 47.00%
Institutional Ownership Percentage: 88.92%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/11/2016Steven ShakInsiderSell5,000$30.39$151,950.00View SEC Filing  
10/10/2016G Bradley ColeCOOSell8,290$30.59$253,591.10View SEC Filing  
10/6/2016James J. VaughnInsiderSell3,000$29.68$89,040.00View SEC Filing  
9/13/2016Steven ShakInsiderSell5,000$26.83$134,150.00View SEC Filing  
8/23/2016Steven ShakInsiderSell5,000$27.24$136,200.00View SEC Filing  
8/15/2016Felix BakerDirectorBuy100,000$27.02$2,702,000.00View SEC Filing  
8/11/2016G Bradley ColeCOOSell5,000$28.87$144,350.00View SEC Filing  
8/8/2016James J. VaughnInsiderSell3,000$28.74$86,220.00View SEC Filing  
7/19/2016Steven ShakInsiderSell5,000$27.42$137,100.00View SEC Filing  
7/6/2016G Bradley ColeCOOSell5,000$26.64$133,200.00View SEC Filing  
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00View SEC Filing  
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.00View SEC Filing  
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.00View SEC Filing  
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.00View SEC Filing  
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.80View SEC Filing  
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00View SEC Filing  
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.00View SEC Filing  
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.00View SEC Filing  
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.00View SEC Filing  
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.00View SEC Filing  
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.00View SEC Filing  
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.00View SEC Filing  
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.40View SEC Filing  
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00View SEC Filing  
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.00View SEC Filing  
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00View SEC Filing  
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View SEC Filing  
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View SEC Filing  
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View SEC Filing  
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View SEC Filing  
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View SEC Filing  
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View SEC Filing  
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View SEC Filing  
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View SEC Filing  
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View SEC Filing  
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View SEC Filing  
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View SEC Filing  
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View SEC Filing  
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View SEC Filing  
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Genomic Health (NASDAQ:GHDX)
DateHeadline logoComprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer … (NASDAQ:GHDX) - October 26 at 5:16 PM logoComprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads to Substantial Cost Savings and Increase in Active Surveillance (NASDAQ:GHDX) - October 26 at 5:16 PM logo9:16 am Genomic Health announces publication in Reviews in Urology of an analysis of the use of the Oncotype DX Genomic Prostate Score in low-risk prostate cancer patients (NASDAQ:GHDX) - October 26 at 5:16 PM
News IconBroker Roundup For Genomic Health, Inc. (NASDAQ:GHDX) - The De Soto Edge (NASDAQ:GHDX) - October 26 at 8:20 AM logoGenomic Health to Announce Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 1, 2016 (NASDAQ:GHDX) - October 25 at 10:08 AM
News IconDo Analysts See Any Upside to Genomic Health, Inc. (NASDAQ:GHDX)? - AR News (NASDAQ:GHDX) - October 23 at 9:43 AM
News IconAnalysts Take the Wheel on Genomic Health, Inc. (NASDAQ:GHDX) Shares and Where They Might Be Headed - CSZ News (NASDAQ:GHDX) - October 16 at 5:03 PM
News IconGenomic Health Inc. (NASDAQ:GHDX) Near to Lift Curtain on September 2016 Earnings - The Voice Registrar (NASDAQ:GHDX) - October 16 at 5:03 PM logoServices Stocks Top Movers and Decliners Recap (NASDAQ:GHDX) - October 14 at 8:15 AM
News IconShares Slogging Higher Over the Last Month: Genomic Health Inc. (NASDAQ:GHDX) - Recall News (NASDAQ:GHDX) - October 13 at 8:19 AM
News IconInsider Trading Review: Genomic Health, Inc. (NASDAQ:GHDX) - The Voice Registrar (NASDAQ:GHDX) - October 13 at 8:19 AM logoThis Innovative Healthcare Stock Belongs In My Portfolio -- What About Yours? (NASDAQ:GHDX) - October 13 at 8:19 AM logoGenomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ™ Liquid Biopsy Mutation Panel (NASDAQ:GHDX) - October 12 at 10:16 AM logoGenomic Health (GHDX) Announces Results from Oncotype SEQ Liquid Select Validation Study (NASDAQ:GHDX) - October 12 at 10:16 AM logoGenomic Health, Inc. (NASDAQ:GHDX) Trading Down – Insider Trading Activity (NASDAQ:GHDX) - October 12 at 10:16 AM logoGenomic Health, Inc. (NASDAQ:GHDX) Mean Price Set At $31.722 - Investor Newswire (NASDAQ:GHDX) - October 11 at 5:27 PM logoGenomic Health (GHDX) Announces Results from Oncotype SEQ ... - (NASDAQ:GHDX) - October 11 at 5:27 PM
News IconGenomic Health announced results from eight Oncotype DX Breast Recurrence Score presentations at ESMO 2016 (NASDAQ:GHDX) - October 10 at 4:58 PM logoMultiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with … (NASDAQ:GHDX) - October 10 at 9:52 AM logoMultiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients (NASDAQ:GHDX) - October 10 at 9:52 AM logoGenomic Health, Inc. (NASDAQ:GHDX) Sell Recommendations At 1 - Investor Newswire (NASDAQ:GHDX) - October 8 at 4:54 PM
News IconStock Upsurging Over Past Week: Genomic Health Inc. (NASDAQ ... - Recall News (NASDAQ:GHDX) - October 8 at 4:54 PM
News IconGenomic Health, Inc. (NASDAQ:GHDX) Updated Broker Price Targets - The De Soto Edge (NASDAQ:GHDX) - October 6 at 5:07 PM
News IconGenomic Health Inc. (NASDAQ:GHDX) Upcoming Earnings: What matter for investors? - The Voice Registrar (NASDAQ:GHDX) - October 4 at 5:03 PM logoCan Shares Of Genomic Health, Inc. (NASDAQ:GHDX) Hit $39.5? - Investor Newswire (NASDAQ:GHDX) - October 2 at 9:38 AM
News IconCurrent Price Targets For Genomic Health, Inc. (NASDAQ:GHDX) - NewsDen (NASDAQ:GHDX) - October 2 at 9:38 AM
News IconLatest Analyst Reports On Genomic Health, Inc. - NewsDen - NewsDen (NASDAQ:GHDX) - September 30 at 10:19 AM
News IconUpgrades And Downgrades For Genomic Health, Inc. (NASDAQ:GHDX) - NewsDen (NASDAQ:GHDX) - September 29 at 10:14 AM logoGenomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized ... - PR Newswire (press release) (NASDAQ:GHDX) - September 29 at 10:14 AM logoGenomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized … (NASDAQ:GHDX) - September 28 at 10:06 AM logoGenomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized Medicine Studies Conducted in Six Countries at ESMO 2016 Congress (NASDAQ:GHDX) - September 28 at 10:06 AM logoAnalysts Expect Genomic Health, Inc. (NASDAQ:GHDX) To Post EPS Of $0.02 - Investor Newswire (NASDAQ:GHDX) - September 25 at 4:43 PM
News IconCowen and Company Cuts Genomic Health Price Target to $27.00 (GHDX) - Petro Global News 24 (NASDAQ:GHDX) - September 23 at 4:56 PM logoGenomic Health, Inc. – Value Analysis (NASDAQ:GHDX) : September 20, 2016 (NASDAQ:GHDX) - September 21 at 9:26 AM
News IconStock Tracker: Earnings & Estimates for Genomic Health, Inc. (NASDAQ:GHDX) - Frisco Fastball (NASDAQ:GHDX) - September 20 at 10:19 AM logoGenomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : September 19, 2016 (NASDAQ:GHDX) - September 19 at 9:47 AM logoGenomic Health : Presolicitation - Genomic Health/Oncotype DXB. Breast Cancer Assay cost per test reportable (NASDAQ:GHDX) - September 16 at 5:03 PM logoETF’s with exposure to Genomic Health, Inc. : September 14, 2016 (NASDAQ:GHDX) - September 14 at 5:17 PM logoGenomic Health, Inc. (NASDAQ:GHDX) Trading Up – Insider Trading Activity (NASDAQ:GHDX) - September 10 at 9:43 AM
News IconPlacing Genomic Health, Inc. (NASDAQ:GHDX) Shares Under the Microscope - Post News (NASDAQ:GHDX) - September 9 at 9:57 AM logoGenomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 7, 2016 (NASDAQ:GHDX) - September 7 at 8:32 AM
News IconShares Slipping Lower Over the Past Month: Genomic Health Inc. (NASDAQ:GHDX) - Post News (NASDAQ:GHDX) - September 1 at 8:06 AM logoGenomic Health to Present at the 2016 Wells Fargo Healthcare Conference (NASDAQ:GHDX) - August 31 at 9:56 AM logoGenomic Health : State Farm Mutual Automobile Insurance Co buys $8,565,480 stake in Genomic Health (GHDX) (NASDAQ:GHDX) - August 28 at 9:38 AM
News IconHow Genomic Health Inc. (NASDAQ:GHDX) trades after earning announcements? - The Independent Republic (NASDAQ:GHDX) - August 27 at 9:49 AM logo[$$] Breast cancer test raises hope chemotherapy can be avoided (NASDAQ:GHDX) - August 25 at 10:11 AM logoWill Genomic Health, Inc. (NASDAQ:GHDX) Hit $39.5 Price Target? - Investor Newswire (NASDAQ:GHDX) - August 21 at 9:39 AM logoInsiders Sell Alphabet, Facebook (NASDAQ:GHDX) - August 19 at 5:09 PM logoGENOMIC HEALTH INC Financials (NASDAQ:GHDX) - August 18 at 5:14 PM logoETF’s with exposure to Genomic Health, Inc. : August 16, 2016 (NASDAQ:GHDX) - August 16 at 5:25 PM


Genomic Health (NASDAQ:GHDX) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by Staff